Symbiotec Pharmalab IPO
Closed MainboardAlready have an account? Apply now
Symbiotec Pharmalab IPO details
Schedule of Symbiotec Pharmalab
| Issue open date | 24 Aug 2026 |
| Issue close date | 27 Aug 2026 |
| UPI mandate deadline | 27 Aug 2026 (5 PM) |
| Allotment finalization | 28 Aug 2026 |
| Refund initiation | 31 Aug 2026 |
| Share credit | 31 Aug 2026 |
| Listing date | 01 Sep 2026 |
| Mandate end date | 11 Sep 2026 |
| Lock-in end date for anchor investors (50%) | 26 Sep 2026 |
| Lock-in end date for anchor investors (remaining) | 25 Nov 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Symbiotec Pharmalab
Symbiotec Pharmalab is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients, contract development and manufacturing solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its active pharmaceutical ingredient portfolio primarily focuses on steroidal products, while its contract development and manufacturing business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house active pharmaceutical ingredient capabilities to support these offerings. Revenue is generated through the sale of active pharmaceutical ingredients, contract development and manufacturing services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets.
Financials of Symbiotec Pharmalab
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 1757 |
| Fresh Issue – Proceeds go to the company | 150 |
| Offer for sale – Proceeds go to the existing investors | 1607 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Repayment or prepayment of borrowings | 112.5 (75%) |
| General corporate purposes | 37.5 (25%) |
Strengths
- Operates an integrated business across APIs, CDMO services and complex injectables.
- Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity.
- Backward integration reduces dependence on external sources for key intermediates.
- Develops differentiated double-chamber injectable products using in-house API capabilities.
- Long-term manufacturing agreements and strategic partnerships support future business growth.
Risks
- Almost all revenue comes from API products, making the business dependent on API demand.
- A large share of revenue comes from a few key customers, and losing them could hurt the business.
- The company depends on key suppliers for raw materials, and supply disruptions could affect operations.
- The company faces intense competition in both the API and CDMO businesses.
- Failure to meet repayment obligations or loan covenants could adversely affect the business and finances.
Allotment Status for Symbiotec Pharmalab
To check your IPO allotment status:
- Visit the MUFG Intime India IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.
Subscription Figures for Symbiotec Pharmalab
Grey Market Premium (GMP) is an unofficial and unregulated metric that may not accurately reflect investor interest. Instead, investors should refer to the IPO subscription data published by the stock exchanges, which is a more reliable indicator of demand.
Subscription numbers as of 05:00 PM on August 27, 2026:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 37.40 | 6433.59 | 172.03x |
| NII | 28.05 | 2065.35 | 73.63x |
| Retail | 65.45 | 848.10 | 12.96x |
| Employees | 0.35 | 5.45 | 15.41x |
| Total | 131.25 | 9352.50 | 71.26x |